Altasciences Featured Content

  1. Understanding Drug Exposure And Drug-Drug Interactions 8/7/2026

    Leverage Altasciences’ DDI expertise to assess interaction risks, generate critical data, and support informed decisions throughout drug development.

  2. Cardiac Safety Assessments In Clinical Trials 8/7/2026

    Assess cardiac risk with expert QT/QTc study design and execution, generating reliable data to inform decisions, reduce development risk, and keep your program moving forward.

  3. Beyond GLP-1: The Evolving Landscape of Metabolic Research 7/15/2026

    GLP-1 therapies are expanding fast, from T2D into obesity, MASH, and neurology. Learn how next-gen multi-agonist incretins, a case study, and market forecasts for patients can shape your strategy.

  4. Strong Regulatory Foundations For Early-Phase Drug Development 6/17/2026

    Discover how an integrated regulatory strategy can help streamline development and accelerate your path to the clinic.

  5. Regulatory Pathways by Region- A Comparative Table 6/17/2026

    Explore key regulatory considerations across major global markets to support more efficient early-phase clinical development planning.

  6. Project Management: Where Science, Strategy, And Operations Converge 5/11/2026

    Stop chasing updates and take control of your program. Learn how our integrated project management services improve visibility, reduce risk, and keep your studies on track.

  7. Clinical Innovation Meets Manufacturing Excellence 10/7/2025

    Discover how our ClinDMO model transforms early drug development with on-demand manufacturing, adaptive formulation, and real-time decision-making to accelerate timelines and optimize API use.

  8. Clinical Trials Without Boundaries: Multi-Site Solutions At Altasciences 8/21/2025

    Altasciences offers flexible clinical trial models — from single-site to multi-center — to accelerate recruitment, expand patient access, and ensure high-quality trials aligned with your protocol.

  9. Maximizing Early-Phase Trials Of CNS-Active Drugs 7/9/2025

    Understand how specialized assessments and early-phase clinical strategies can generate meaningful safety, pharmacology, and proof-of-concept data.

  10. Challenges With Hallucinogens, Psychedelics, And Entactogens 5/9/2025

    This eBook examines the complex regulatory landscape and the preclinical, clinical, and manufacturing challenges involved in developing Schedule 1 therapeutics.